MedTrace Logo

Enzalutamide Plus Talazoparib for the Treatment of Hormone Sensitive Prostate Cancer (ZZ-First)

NCT04332744 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 54

Last updated 2025-05-11

No results posted yet for this study

Summary

This is a multicenter, open-label, randomized, two-arm, phase II clinical trial to evaluate the efficacy and safety of talazoparib (PF-06944076) in combination with enzalutamide in patients with metastatic hormone-naïve prostate cancer (mHNPC)

Conditions

Interventions

DRUG

Enzalutamide

Enzalutamide capsules orally once daily and continuously (160 mg) in 28-day cycles (every four weeks)

DRUG

Talazoparib

Talazoparib capsules orally once daily and continuously (0.5 mg) in 28-day cycles (every four weeks)

Sponsors & Collaborators

  • Pfizer

    collaborator INDUSTRY

  • MedSIR

    lead OTHER

Principal Investigators

  • Joaquin Mateo · VHIO

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-09-02
Primary Completion
2025-05-06
Completion
2025-05-06

Countries

  • Spain

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04332744 on ClinicalTrials.gov